Lexeo Therapeutics, Inc.

LXEO · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
55
SEC Filings

Business Summary

PART I Item 1. B usiness. Overview We are a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. We are advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including Friedreich ataxia, or FA, cardiomyopathy, plakophilin-2, or PKP2, arrhythmogenic cardiomyopathy, and other devastating diseases with high unmet need. Our mos...

Next Earnings

Q2 FY2026 — expected 2026-08-13

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionLXEOdiscussed_in_filing Cybersecurity
topic_mentionLXEOdiscussed_in_filing Cybersecurity
topic_mentionLXEOdiscussed_in_filing Healthcare & Bio
topic_mentionLXEOdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-302025-12-310001193125-26-132085EDGAR110K words
2025-03-242024-12-310000950170-25-043486EDGAR—
2024-03-112023-12-310000950170-24-028941EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-052025-09-300001193125-25-265757EDGAR78K words
2025-08-142025-06-300000950170-25-108427EDGAR—
2025-05-122025-03-310000950170-25-068536EDGAR—
2024-11-132024-09-300000950170-24-125943EDGAR—
2024-08-122024-06-300000950170-24-095057EDGAR—
2024-05-092024-03-310000950170-24-056247EDGAR—
2023-12-112023-09-300000950170-23-069192EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-300001193125-26-131792EDGAR2K words
2026-02-050001193125-26-039425EDGAR—
2026-01-270001193125-26-023339EDGAR—
2026-01-120001193125-26-010091EDGAR—
2025-11-050001193125-25-265755EDGAR—
2025-10-170001193125-25-242652EDGAR—
2025-10-070001193125-25-232514EDGAR—
2025-08-140000950170-25-108426EDGAR—
2025-06-300000950170-25-091671EDGAR—
2025-05-270000950170-25-077377EDGAR—

55 total filings indexed. 35 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001907108
TickerLXEO
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 8175d3362a5c9cc7ae18a9735e0b618ac1847613b836dc691d14691408c9a1b3
parent: 3586acda292b81ef60381470a783caaaa7e81b6909374a4fc5e9aca2c65ea3fd
content hash: 5118676f0a7a091aceaf8262e08d899379ac31d8838fb5f4b5ef30c217d0fc85
signed: 2026-04-13T04:46:08.350Z
sources: 10 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf